Trial Profile
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thrombosis
- Focus Therapeutic Use
- 12 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
- 12 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2020.
- 26 Jun 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2017.